Clinical Study of CEA Targeting Chimeric Antigen Receptor T Lymphocytes（CAR-T） for CEA Positive Advanced Malignant Solid Tumors

This trial is testing a new CAR-T cell therapy that targets a protein called CEA, which is found on the surface of many solid tumors. It is being studied in patients with advanced colorectal, esophageal, gastric, or pancreatic cancer whose cancer tests positive for CEA. **You may be eligible if:** - You are 18 or older with advanced, recurrent, or metastatic colorectal, esophageal, gastric, or pancreatic cancer - Your tumor tests positive for CEA (at least 10% of cancer cells have CEA on their surface) - You have already tried at least two prior treatment regimens without success - You have at least one measurable tumor - You have good physical functioning (ECOG score 0–2) - Your blood counts, heart, liver, and kidney function meet the required levels **You may NOT be eligible if:** - Your cancer has spread to the brain or the lining of the brain - You have active autoimmune disease or require immunosuppressive therapy - You have an active, uncontrolled infection - You have active hepatitis B, hepatitis C, HIV, or syphilis - You are pregnant or breastfeeding - You have significant heart disease Talk to your doctor to see if this trial is right for you.